60 Degrees Pharmaceuticals Inc. (SXTP)
(Delayed Data from NSDQ)
$1.35 USD
-0.04 (-2.54%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.34 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SXTP 1.35 -0.04(-2.54%)
Will SXTP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SXTP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SXTP
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
SXTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
OptiNose (OPTN) Reports Break-Even Earnings for Q3
Other News for SXTP
60 Degrees Pharmaceuticals (SXTP) Partners with Tulane University for Lyme Disease Research | ...
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine ...
60 Degrees Pharmaceuticals, Tulane University sign research agreement
12 Health Care Stocks Moving In Tuesday's Intraday Session
60 Degrees Pharmaceuticals (SXTP) Announces Public Offering Details